Jiangsu Hansoh Pharmaceutical Co., Ltd.

New phase 1 trial NCT07615413 posted by Jiangsu Hansoh Pharmaceutical Co., Ltd.: "Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.". New trial on a phase 1 not yet recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 102 days ago.

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.